Latest News & Features
Americas
“There’s one stick with this carrot—the whistleblower protection law,” explained Anne Elise Li, IP counsel at Crowell & Moring, in reference to the Defend Trade Secrets Act. 22 June 2017
Americas
The biotechnology industry is at a crossroads over 35 USC section 101, which covers patent sub-ject matter eligibility. 22 June 2017
Europe
Collaboration and sharing are important goals for Bayer in seeking to protect innovations with IP rights, as Richard Rees explains in an interview with LSIPR. 22 June 2017
Big Pharma
Panellists discussed the potential impact of the UK’s decision to leave the EU on patents yesterday at the 2017 BIO International Convention. 22 June 2017
Africa
Pfizer and Takeda have joined together with non-profit BIO Ventures for Global Health and the African Organisation for Research and Training in Cancer to launch the African Access Initiative. 22 June 2017
Americas
Academic patents and their subsequent licensing contributed up to $1.3 trillion to US industry gross output between 1996 and 2015, the Biotechnology Innovation Organization has found. 22 June 2017
Americas
Florida-based company Belcher Pharmaceuticals has filed a complaint against Hospira for patent infringement. 21 June 2017
Biotechnology
Google’s parent company Alphabet has invested $300 million in a new fund that will buy stakes in European biotech companies. 21 June 2017
Europe
With the US Supreme Court set to decide the biosimilars dispute between Amgen and Sandoz, LSIPR examines the possible outcomes and implications for those in the industry. 21 June 2017
Americas
The perceived problem with 35 USC section 101 is a “fundamental question of national innovation policy”, claimed Kevin Rhodes, vice president and chief IP counsel at multinational conglomerate 3M. 21 June 2017